Natco Pharma surges on getting EIR from USFDA for API facility in Hyderabad | | Udaipur News | Udaipur Latest News | udaipur local news । Udaipur Updates
Home / BUSINESS / Natco Pharma surges on getting EIR from USFDA for API facility in Hyderabad

Natco Pharma surges on getting EIR from USFDA for API facility in Hyderabad

Natco Pharma is currently trading at Rs. 590.80, up by 9.60 points or 1.65% from its previous closing of Rs. 581.20 on the BSE.

The scrip opened at Rs. 585.90 and has touched a high and low of Rs. 598.15 and Rs. 579.50 respectively. So far 2528 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 801.20 on 05-Nov-2018 and a 52 week low of Rs. 482.00 on 28-May-2019.

Last one week high and low of the scrip stood at Rs. 607.45 and Rs. 572.30 respectively. The current market cap of the company is Rs. 10628.54 crore.

The promoters holding in the company stood at 49.01%, while Institutions and Non-Institutions held 28.24% and 22.75% respectively.

Natco Pharma has received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at its Active Pharmaceutical Ingredient (API) facility in Mekaguda Village, Hyderabad which was conducted during the period August 5-9, 2019.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Please share this news